The latest announcement is out from Abbisko Cayman Limited ( (HK:2256) ).
Abbisko Cayman Limited announced an increase in shareholding by its founder and CEO, Dr. Xu Yao-Chang, who purchased 30,000 shares, reflecting his confidence in the company’s growth prospects. Additionally, the company has repurchased 4,798,000 shares under its Share Repurchase Plan, indicating that the current trading price undervalues its business potential.
More about Abbisko Cayman Limited
Abbisko Cayman Limited is a company incorporated in the Cayman Islands, operating in the biopharmaceutical industry. It focuses on the discovery and development of innovative medicines, with a market focus on addressing unmet medical needs.
Average Trading Volume: 6,400,086
Technical Sentiment Signal: Buy
Current Market Cap: HK$5.41B
See more data about 2256 stock on TipRanks’ Stock Analysis page.